Why Wegovy (Semaglutide 2.4 mg) Causes Vomiting: The Biology Explained

How common is vomiting on Wegovy?

In three pooled placebo-controlled trials, 2,116 adults with obesity or overweight received Wegovy 2.4 mg once weekly for up to 68 weeks and 1,261 received placebo [1]. Vomiting was reported by 24% versus 6%, nausea by 44% versus 16%, diarrhea by 30% versus 16%, and any gastrointestinal reaction by 73% versus 47% [1]. Treatment was stopped for adverse reactions by 6.8% versus 3.2%, and vomiting was the reason in 1.2% versus 0% [1].

In the 68-week trial in patients aged 12 and older (133 on semaglutide 2.4 mg, 67 on placebo), vomiting occurred in 36% versus 10% and nausea in 42% versus 18% [1].

The gut: semaglutide slows the stomach

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1; it binds and activates the GLP-1 receptor and delays gastric emptying [1]. The label states that Wegovy delays gastric emptying and may affect absorption of oral medicines taken at the same time [1].

The clearest human measurement of that delay is small. In a crossover trial, 30 adults with obesity received semaglutide escalated to 1.0 mg weekly or placebo for 12 weeks each, and gastric emptying was assessed with a paracetamol absorption test [3]. In the first hour after a standard meal, paracetamol exposure was about 27% lower on semaglutide than on placebo (ratio 0.73, 95% CI 0.61 to 0.87) [3]. Across the full 5 hours, emptying did not differ statistically between treatments [3]. That trial used 1.0 mg, not the 2.4 mg weight-management dose.

The brainstem: GLP-1 receptors outside the barrier

The area postrema is a small structure at the base of the fourth ventricle that lacks a normal blood-brain barrier and is involved in triggering nausea and vomiting. In rats, semaglutide did not cross the blood-brain barrier but reached the brainstem, septal nucleus and hypothalamus through the circumventricular organs and other sites next to the ventricles. It induced activation in 10 brain areas, and in the area postrema it increased expression of prolactin-releasing hormone and tyrosine hydroxylase [2].

That study examined food intake and body weight, not vomiting. Slower gastric emptying and effects on brainstem pathways are both possible explanations for vomiting on Wegovy; the human study measured the stomach effect at 1 mg and the rat study found brainstem effects, and neither established how much each contributes to vomiting at 2.4 mg.

Does dose matter?

Vomiting was more frequent at the higher dose. In the two 72-week trials behind the 7.2 mg dose (1,311 adults on 7.2 mg, 304 on 2.4 mg, 303 on placebo), vomiting was reported by 22%, 16% and 6% respectively, and 3%, 3% and 0.3% stopped treatment for gastrointestinal reasons [1].

The label's schedule steps through 0.25 mg in weeks 1 to 4, 0.5 mg in weeks 5 to 8, 1 mg in weeks 9 to 12, 1.7 mg in weeks 13 to 16, then maintenance at 1.7 or 2.4 mg from week 17 [1]. The label says to follow this escalation to reduce the risk of gastrointestinal adverse reactions, and that if a dose is not tolerated, consider delaying escalation for 4 weeks [1].

What the label treats as serious

Severe gastrointestinal adverse reactions occurred in 4.1% of people on Wegovy injection versus 0.9% on placebo [1]. Wegovy is not recommended in patients with severe gastroparesis, and postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. Acute kidney injury from volume depletion occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, and often after gastrointestinal fluid loss [1].

The label also flags acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says Wegovy should be discontinued [1].

What is not known

We found no published data on how long vomiting lasts at a stable dose or on what proportion of people stop vomiting as treatment continues. The rates above describe how many people reported vomiting across whole trials, not how long individual episodes ran.